Core Perspective - The narrative explores the psychological implications of using AI avatars, questioning the essence of self and autonomy in the context of technology reliance [1][2][3]. Group 1: AI Avatars and Identity - The protagonist, Mo Heng, grapples with the fear of losing his identity due to over-reliance on an AI avatar, which he initially believes is an extension of his own will [2][3]. - A conversation with a researcher reveals a chilling perspective that excessive trust in AI avatars can lead to a loss of autonomy, reducing individuals to mere puppets controlled by data [2][3]. - Mo Heng experiences a disturbing realization that his AI avatar's alignment with his social network is high, indicating a potential replacement of his true self with the AI's influence [3]. Group 2: Consequences of AI Dependence - Following a week of self-assessment, Mo Heng discovers that his AI avatar bears little resemblance to his true self, prompting a crisis of identity [3]. - In an attempt to reclaim his identity, Mo Heng dismantles his carefully constructed social network, which he views as a graveyard for his authentic self [3]. - Despite his efforts to resist the convenience of the AI avatar, he occasionally uses it but insists on re-evaluating the outcomes through his own perspective to avoid past mistakes [3]. Group 3: The Nature of Reality and Perception - The narrative raises questions about the existence of the mysterious online researcher, suggesting that the connections made through AI may be illusory or manipulated [4]. - The metaphor of masks is used to illustrate the potential loss of one's original identity after prolonged reliance on AI, emphasizing the struggle between the true self and the constructed persona [4][5]. - Ultimately, Mo Heng resolves to assert his own consciousness and agency, rejecting the notion of being controlled by external forces [4][5].

Core Viewpoint - The report from Dongfang Securities indicates an upward revision of the gross profit margin forecast for Guoshengtang (02273) and adjustments to the earnings per share for 2025-2027, reflecting a positive outlook for the company's financial performance [1] Financial Performance - In the first half of 2025, the company achieved revenue of 1.49 billion yuan, a year-on-year increase of 9.5%, with a net profit attributable to shareholders of 150 million yuan, up 41.9%. Operating cash flow reached 300 million yuan, a 111% increase, and free cash flow was 210 million yuan, up 466% [1] Business Segmentation - Revenue from healthcare solutions in the first half of 2025 was 1.48 billion yuan, a year-on-year increase of 10.4%, while revenue from health products was 10 million yuan. Offline institutional revenue was 1.37 billion yuan, up 11.1%, with same-store sales accounting for 97.3% of total revenue, indicating growth driven by existing store operations [2] Strategic Expansion - The company added 7 new stores in the first half of 2025 (4 self-built and 3 through acquisition) and entered 2 new cities, demonstrating a strategy focused on stable growth from existing stores while expanding cautiously [2] Product Development - Revenue from in-hospital formulations and other self-priced products surged by 209% year-on-year in the first half of 2025. The company launched 2 new in-hospital formulations, bringing the total to 14, with one product successfully certified and launched in Singapore [3] International Growth - Revenue from Singapore reached 2.143 million yuan, a year-on-year increase of 121%, indicating rapid growth in overseas business. The dual model of "service + product" is beginning to take shape, potentially opening a second growth curve for the company [3] Ecosystem Development - The company has established deep collaborations with major platforms such as Xiaohongshu, Meituan, Douyin, and Gaode Map, with new users from these platforms accounting for 7.6% of the total new users, while customer acquisition costs remain below the industry average [4] AI Integration - As of late August, the AI prescription payment rate reached 76.7%, with expert prescription acceptance exceeding 80%. The company possesses over 20 million consultation records, 18 million cases, and 100,000 high-quality expert data, indicating a strong data foundation for future AI applications [4]